HER2- breast cancer
Oncology · 2023–2023
1decision
1medicine
1carried consumer input
14individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| olaparib Adjuvant treatment of HER2-negative high-risk early breast cancer with confirmed germline BRCA1 or BRCA2 mutation in patients who have previously been treated… | Nov 2023 | Recommended | 14 individuals Medical Oncology Group · Breast Cancer Network Australia |
Who spoke
Medical Oncology Group · Breast Cancer Network Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.